Ciraparantag
Tier C — Watch / tradeCiraparantag
Targets：F10
Indications (approved)：出血性疾病
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| CIRA-001 | - | 3,3'-(piperazine-1,4-diyl)bis(propan-1-amine) |
| CIRA-002 | 35897-34-8 | (S)-2-((tert-butoxycarbonyl)amino)-5-guanidinopentanoic acid hydrochloride |
| CIRA-003 | 1438492-46-6 | di-tert-butyl ((2S,2'S)-((piperazine-1,4-diylbis(propane-3,1-diyl))bis(azanediyl))bis(5-guanidino-1-oxopentane-2,1-diyl))dicarbamate |
Frequently asked questions
What are the approved indications of Ciraparantag?
Approved indications include: 出血性疾病.
When does the Ciraparantag patent expire?
No public expiry year is available for Ciraparantag yet; this page updates once verified.
How many synthesis routes are recorded for Ciraparantag?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Ciraparantag intermediates?
All intermediates in Ciraparantag routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Ciraparantag intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12